Similar articles

• Association between cardiac biomarkers and the development of ESRD in patients with type 2 diabetes mellitus, anemia, and CKD.

  Desai AS, Toto R, Jarolim P, Uno H, Eckardt KU, Kewalramani R, Levey AS, Lewis EF, McMurray JJ, Parving HH, Solomon SD, Pfeffer MA. Desai AS, et al. Am J Kidney Dis. 2011 Nov;58(5):717-28. doi: 10.1053/j.ajkd.2011.05.020. Epub 2011 Aug 5. Am J Kidney Dis. 2011. PMID: 21820220
• Plasma high-sensitivity troponin T predicts end-stage renal disease and cardiovascular and all-cause mortality in patients with type 1 diabetes and diabetic nephropathy.

  Galsgaard J, Persson F, Hansen TW, Jorsal A, Tarnow L, Parving HH, Rossing P. Galsgaard J, et al. Kidney Int. 2017 Nov;92(5):1242-1248. doi: 10.1016/j.kint.2017.04.018. Epub 2017 Jul 14. Kidney Int. 2017. PMID: 28712855
• Comment on Hillis et al. The relative and combined ability of high-sensitivity cardiac troponin T and N-terminal pro-B-type natriuretic Peptide to predict cardiovascular events and death in patients with type 2 diabetes. Diabetes care 2014;37:295-303.

  Neuhold S, Pacher R, Hülsmann M. Neuhold S, et al. Diabetes Care. 2014 Jun;37(6):e152-3. doi: 10.2337/dc14-0052. Diabetes Care. 2014. PMID: 24855180 No abstract available.
• Use of cardiac biomarkers in end-stage renal disease.

  Wang AY, Lai KN. Wang AY, et al. J Am Soc Nephrol. 2008 Sep;19(9):1643-52. doi: 10.1681/ASN.2008010012. Epub 2008 Mar 5. J Am Soc Nephrol. 2008. PMID: 18322158 Review.
• Cardiac biomarkers in haemodialysis patients: the prognostic value of amino-terminal pro-B-type natriuretic peptide and cardiac troponin T.

  Sommerer C, Giannitsis E, Schwenger V, Zeier M. Sommerer C, et al. Nephron Clin Pract. 2007;107(3):c77-81. doi: 10.1159/000108647. Epub 2007 Sep 21. Nephron Clin Pract. 2007. PMID: 17890874 Review.